Phosphoinositide 3-Kinase Therapy in Diabetic Cardiomyopathy: Unravelling an Enigma
Yaguang Bi,Yingmei Zhang,Jun Ren
DOI: https://doi.org/10.1152/ajpheart.00160.2020
2020-01-01
Abstract:Editorial FocusPhosphoinositide 3-kinase therapy in diabetic cardiomyopathy: unravelling an enigmaYaguang Bi, Yingmei Zhang, and Jun RenYaguang BiDepartment of Cardiology, and Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital Fudan University, Shanghai, ChinaCenter for Cardiovascular Research and Alternative Medicine, University of Wyoming College of Health Sciences, Laramie, Wyoming, Yingmei ZhangDepartment of Cardiology, and Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital Fudan University, Shanghai, China, and Jun RenDepartment of Cardiology, and Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital Fudan University, Shanghai, ChinaCenter for Cardiovascular Research and Alternative Medicine, University of Wyoming College of Health Sciences, Laramie, WyomingPublished Online:08 Apr 2020https://doi.org/10.1152/ajpheart.00160.2020This is the final version - click for previous versionMoreSectionsPDF (272 KB)Download PDFDownload PDFPlus ToolsExport citationAdd to favoritesGet permissionsTrack citations ShareShare onFacebookTwitterLinkedInEmail Diabetes mellitus, the most prevalent noncommunicable epidemic threat, is expected to reach an astonishing 600 million by year 2035 (1). Cardiovascular anomalies are commonly seen in diabetes, contributing to the high morbidity and mortality in patients with diabetes (5, 9, 11). In particular, undesired geometric and functional changes develop in diabetic hearts, independent of any macro- and microvascular comorbidities, leading to pronounced cardiac remodeling, systolic and diastolic dysfunction, including compromised myocardial contractile capacity, and prolonged duration and reduced velocity of contraction and relaxation, a condition commonly known as diabetic cardiomyopathy, first described by Rubler and colleagues in 1972 (5, 9, 11). Clinical observations using electrocardiogram and echocardiography have unveiled substantial changes in diabetic human hearts including altered left ventricular ejection time, preejection duration, left ventricular filling time, action potential duration, ventricular wall stiffness, and ejection fraction (5, 9, 11). Ample cellular and molecular mechanisms have been postulated for the pathogenesis of diabetic cardiomyopathy, encompassing mitochondrial injury, oxidative stress, inflammation, apoptosis, autophagy failure, disturbed energy metabolism, and intracellular Ca2+ defect (5, 9). Preclinical evidence over the past decades has also indicated a cadre of cell signaling therapeutic targets and strategies, such as antioxidative [nuclear factor erythroid 2-like 2 (Nrf2) activators, curcumin products, vitamins, and metallothionein derivatives], antifibrotic (melatonin, resveratrol, relaxin, and phosphodiesterase 5 inhibitors), anti-inflammatory [luteolin, Klotho, ursolic acid, epigallocatechin-3-gallate, statins, Toll-like receptor 4 (TLR4) inhibitors, NOD-like receptor family pyrin domain containing 3 (NLRP3) inhibitors, and tumor necrosis factor-α (TNF-α) inhibitors] and antiapoptotic (Fisetin, hydrogen sulfide, and lipid lowering statins) agents (5, 9, 11). Many of these interventions involve multiple therapeutic benefits such as concurrent antioxidation and anti-inflammation. Nonetheless, subsequent clinical trials for these therapeutic maneuvers, although somewhat promising for initial results (9), remain to be fully validated. Much more work is still warranted to better understand the pathogenesis of such myopathic condition in patients with diabetes and in particular type 2 diabetes (T2D), which is much more prevalent in comparison with type 1 diabetic (T1D) populations.In a recent issue of the American Journal of Physiology-Heart and Circulatory Physiology, Prakoso and colleagues (8) reported that administration of recombinant adeno-associated viral vectors carrying a constitutively active phosphoinositide 3-kinase [PI3K (p110α)] construct (rAAV6-caPI3K) effectively ameliorated diabetic cardiac remodeling and contractile dysfunction in a T2D model using a combination of high-fat diet (42% energy intake from fat) and streptozotocin (3 consecutive 55 mg/kg body wt ip). These authors noted evident cardiac anomalies in this preclinical T2D model as manifested by impaired left ventricular systolic function (fractional shortening and velocity of circumferential fiber shortening) and unfavorable cardiac remodeling (hypertrophy and interstitial and perivascular collagen deposition). Strikingly, T2D-induced cardiac dysfunction and remodeling were effectively rescued by a single delivery of cardiac targeted rAAV6-caPI3K. Mechanistically, these authors revealed decreased levels of reactive oxygen species (ROS) and endoplasmic reticulum (ER) stress in response to the cardiac-selective rAAV6-caPI3K delivery (Fig. 1), which seems to underscore functional and geometric benefits from PI3K (p110α) gene therapy (8). Earlier finding from this group reported that the very same cardiac rAAV6-caPI3K (p110α) gene delivery greatly limits cardiac remodeling, contractile dysfunction, ER stress, and apoptosis in streptozotocin (5 consecutive 55 mg/kg body wt ip)-induced T1D model, possibly through regulation of NADPH oxidase (7). It is noteworthy that rAAV6-caPI3K was delivered following the establishment of diabetic cardiomyopathy phenotype in both T2D and T1D models (7, 8), mimicking a clinically relevant situation. These findings collectively denote an important role for PI3K in the novel therapeutics against diabetic cardiomyopathy.Fig. 1.Schematic diagram depicting possible mechanism(s) of involved in phosphoinositide 3-kinase (PI3K)α-induced beneficial effects against diabetes-induced anomalies in cardiac contractile function, morphology, and cell survival. PI3Kα (p110α) inhibits endoplasmic reticulum (ER) stress and oxidative stress to counteract diabetic insult to the heart. rAAV6-caPI3K, recombinant adeno-associated viral vectors carrying a constitutively active PI3K (p110α) construct; ROS, reactive oxygen species.Download figureDownload PowerPointPI3Ks belong to a large family of heterodimer lipid/protein kinases that serve as a central regulator for both physiological and pathophysiological processes, including cell growth and cell survival (2, 6). PI3Ks (class I) comprise a catalytic subunit (p110α, p110β, or p110δ), which is bound to the regulatory subunits (p85 and p55). Ample findings have depicted a rather important role for the p110α subunit along with its downstream signaling molecule Akt in the regulation of insulin signaling and metabolic profiles in particular in the etiology of insulin resistance, obesity, and diabetes mellitus (2–4, 6). PI3Kα ablation is embryonically lethal, whereas adipose PI3K (p110α) deletion results in overt adiposity and body weight gain (2). Likewise, the kinase-dead knock-in allele of p110α of PI3K displays hyperinsulinemia and impaired glucose tolerance, a phenotype reminiscent of those seen with deficiency in p85 regulatory subunit of PI3K. Mice with diminished cardiac PI3K (p110α) activity elicited by a dominant negative (dn) PI3K (p110α) mutant or deletion of p85 subunits exhibited cardiac atrophy at basal condition and dampened hypertrophic response upon exercise. To the contrary, transgenic mice with a constitutively active PI3K (p110α) mutant exhibited physiological cardiac hypertrophy under basal conditions and improved cardiac function or lifespan in stress conditions such as myocardial infarction or dilated cardiomyopathy (10). With genetically engineered mouse models, both beneficial and detrimental roles for PI3Kα have been noted in cardiovascular pathophysiological processes (2). In this context, governance of PI3K signaling, in particular p110α, is cardinal to the regulation of systemic glucose and lipid metabolism. However, limited availability of PI3K activators along with pharmacokinetic shortfalls such as poor bioavailability and fast metabolism, chemical instability, and safety/toxicity concerns have largely limited the clinical application of PI3K activators. Moreover, overstimulation of PI3K and its downstream signaling molecule Akt has been demonstrated to trigger cardiac hypertrophy and is deemed detrimental in certain conditions such as aging (4). To this end, the hunt for more specific or tissue-selective PI3K modulators may represent a novel approach in pharmacotherapy for the management of diabetes and diabetic complications. Although this study from Prakoso and colleagues (8) has unveiled the therapeutic potential of PI3K activation in the treatment and management of diabetic cardiomyopathy, more questions remain to be answered. First, can PI3K analog be employed for dyslipidemia and obesity-induced cardiovascular anomalies, and if so, what is the mechanism(s) of action behind PI3K (p110α)-elicited benefit against obesity-induced cardiovascular dysfunction? Given the well-established role of PI3K in insulin signaling and lipid metabolism (2) and close association between obesity and T2D (11), possible added benefit (or risk) of PI3K-targeted therapy in obese T2D should be weighed. Second, it was reported that loss of PI3Kα using genetically engineered mice failed to reveal any inherently pathological changes to the heart in otherwise healthy mice (6), somewhat inconsistent with those reported in mice overexpressing a dnPI3K (p110α) mutant or with deletion of p85 subunits (10). Thus, the onset and development of diabetic cardiomyopathy is unlikely originated from defects in PI3Kα itself. What is the precise role of PI3Kα in the pathogenesis of diabetic cardiomyopathy? Are there any other confounding factors to launch the “diabetic cardiomyopathy missile” in the presence of PI3K abnormality? At this time, proper clinical management for diabetic cardiomyopathy mainly encompasses proper control of glucose and lipid metabolism, correction of coronary artery diseases, hypertension and inflammation, along with nonpharmacotherapies such as lifestyle modification and exercise. Many of these measures should help to harness the PI3K signaling (such as exercise training), although the precise mechanism(s) of action remains elusive. Last but not the least, improper or chronic activation of PI3K-Akt signaling cascade may bring significant clinical concerns such as cancer prevalence, thus pharmacological therapies targeting PI3K may have to be handled with special caution under certain clinical scenarios.GRANTSThis work was supported in part by National Science Foundation Grant NSF-81770261.DISCLOSURESNo conflicts of interest, financial or otherwise, are declared by the authors.AUTHOR CONTRIBUTIONSY.B., Y.Z., and J.R. drafted, edited, and revised manuscript.REFERENCES1. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 103: 137–149, 2014. doi:10.1016/j.diabres.2013.11.002. Crossref | PubMed | ISI | Google Scholar2. Hopkins BD, Goncalves MD, Cantley LC. Insulin-PI3K signalling: an evolutionarily insulated metabolic driver of cancer. Nat Rev Endocrinol. 2020 March 3. [Epub ahead of print.] 2020. doi:10.1038/s41574-020-0329-9. Crossref | PubMed | ISI | Google Scholar3. Hu N, Ren J, Zhang Y. Mitochondrial aldehyde dehydrogenase obliterates insulin resistance-induced cardiac dysfunction through deacetylation of PGC-1α. Oncotarget 7: 76398–76414, 2016. doi:10.18632/oncotarget.11977. Crossref | PubMed | Google Scholar4. Hua Y, Zhang Y, Ceylan-Isik AF, Wold LE, Nunn JM, Ren J. Chronic Akt activation accentuates aging-induced cardiac hypertrophy and myocardial contractile dysfunction: role of autophagy. Basic Res Cardiol 106: 1173–1191, 2011. doi:10.1007/s00395-011-0222-8. Crossref | PubMed | ISI | Google Scholar5. Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circ Res 122: 624–638, 2018. doi:10.1161/CIRCRESAHA.117.311586. Crossref | PubMed | ISI | Google Scholar6. McLean BA, Zhabyeyev P, Patel VB, Basu R, Parajuli N, DesAulniers J, Murray AG, Kassiri Z, Vanhaesebroeck B, Oudit GY. PI3Kα is essential for the recovery from Cre/tamoxifen cardiotoxicity and in myocardial insulin signalling but is not required for normal myocardial contractility in the adult heart. Cardiovasc Res 105: 292–303, 2015. doi:10.1093/cvr/cvv016. Crossref | PubMed | ISI | Google Scholar7. Prakoso D, De Blasio MJ, Qin C, Rosli S, Kiriazis H, Qian H, Du XJ, Weeks KL, Gregorevic P, McMullen JR, Ritchie RH. Phosphoinositide 3-kinase (p110α) gene delivery limits diabetes-induced cardiac NADPH oxidase and cardiomyopathy in a mouse model with established diastolic dysfunction. Clin Sci (Lond) 131: 1345–1360, 2017. doi:10.1042/CS20170063. Crossref | PubMed | ISI | Google Scholar8. Prakoso D, De Blasio MJ, Tate M, Kiriazis H, Donner DG, Qian H, Nash D, Deo M, Weeks KL, Parry LJ, Gregorevic P, McMullen JR, Ritchie RH. Gene therapy targeting cardiac phosphoinositide 3-kinase (p110α) attenuates cardiac remodeling in type 2 diabetes. Am J Physiol Heart Circ Physiol 318: H840–H852, 2020. doi:10.1152/ajpheart.00632.2019. Link | ISI | Google Scholar9. Tan Y, Zhang Z, Zheng C, Wintergerst KA, Keller BB, Cai L. Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence. Nat Rev Cardiol. 2020 February 20. [Epub ahead of print.] doi:10.1038/s41569-020-0339-2. Crossref | PubMed | ISI | Google Scholar10. Weeks KL, Gao X, Du XJ, Boey EJ, Matsumoto A, Bernardo BC, Kiriazis H, Cemerlang N, Tan JW, Tham YK, Franke TF, Qian H, Bogoyevitch MA, Woodcock EA, Febbraio MA, Gregorevic P, McMullen JR. Phosphoinositide 3-kinase p110α is a master regulator of exercise-induced cardioprotection and PI3K gene therapy rescues cardiac dysfunction. Circ Heart Fail 5: 523–534, 2012. doi:10.1161/CIRCHEARTFAILURE.112.966622. Crossref | PubMed | ISI | Google Scholar11. Zhang Y, Whaley-Connell AT, Sowers JR, Ren J. Autophagy as an emerging target in cardiorenal metabolic disease: From pathophysiology to management. Pharmacol Ther 191: 1–22, 2018. doi:10.1016/j.pharmthera.2018.06.004. Crossref | PubMed | ISI | Google ScholarAUTHOR NOTESAddress for correspondence: J. Ren, Univ. of Wyoming College of Health Sciences, 1000 E. University Ave., Dept. 3375, Laramie, WY 82071 (e-mail: [email protected]edu). Previous Back to Top Next FiguresReferencesRelatedInformationRelated articlesGene therapy targeting cardiac phosphoinositide 3-kinase (p110α) attenuates cardiac remodeling in type 2 diabetes 24 Mar 2020American Journal of Physiology-Heart and Circulatory PhysiologyCited ByHyperglycemic memory in diabetic cardiomyopathy18 December 2021 | Frontiers of Medicine, Vol. 25Weighted Gene Co-Expression Network Analysis Identifies ANGPTL4 as a Key Regulator in Diabetic Cardiomyopathy via FAK/SIRT3/ROS Pathway in Cardiomyocyte20 September 2021 | Frontiers in Endocrinology, Vol. 12Histone Deacetylases in the Pathogenesis of Diabetic Cardiomyopathy22 July 2021 | Frontiers in Endocrinology, Vol. 12Cardioprotective effects of melatonin: Focusing on its roles against diabetic cardiomyopathyBiomedicine & Pharmacotherapy, Vol. 128Metformin Ameliorates Diabetic Cardiomyopathy by Activating the PK2/PKR Pathway19 May 2020 | Frontiers in Physiology, Vol. 11 More from this issue > Volume 318Issue 5May 2020Pages H1029-H1031 Copyright & PermissionsCopyright © 2020 the American Physiological Societyhttps://doi.org/10.1152/ajpheart.00160.2020PubMed32167783History Received 9 March 2020 Accepted 11 March 2020 Published online 8 April 2020 Published in print 1 May 2020 Metrics Downloaded 286 times
What problem does this paper attempt to address?
-
Expression Changes Of Mitogen-Actilvated Protelin Kinase Phosphatase-1 (Mkp-1) In Myocardium Of Streptozotocin-Induced Diabetic Rats
Y. Weng,F. Shen,J. Li,Y. Shen,X. Zhang
DOI: https://doi.org/10.1055/s-2007-973060
2007-01-01
Experimental and Clinical Endocrinology & Diabetes
Abstract:MAP Kinase Phosphatase-1 (MKP-1) is a dual specific phosphatase selective for MAP kinases, and was believed to implicate in the development of cardiac hypertrophy. However, whether MKP-1 is involved in the pathogenesis of diabetic cardiomyopathy is still unknown. We employed streptozotocin (STZ)-induced diabetic SpragueDawley rats to study the alteration of the MKP-1 expressions in the left ventricular myocardium in diabetic and normal groups by immunchistochernistry and real-time quantitative reverse transcription-polymerase chain reaction. The weight, blood sugar and urine sugar were measured before and after model induction in both control and diabetic groups. Changes of heart ultrastructure were analyzed by using transmission electron microscopy. The data of weight, blood sugar and urine sugar indicated no significant difference between the two groups before animal model induction. Eight weeks after the induction of diabetes, the differences between the control and the diabetic groups in weight, blood sugar and urine sugar were significant (P < 0.01). When compared with control, diabetic myocardium ultrastructural changes included myofibrillar disarrangements, mitochondria disruption, and increase in nuclear membrane invaginations. A significant decrease of MKP1 expression was observed in the diabetic rats' myocardium (P < 0.01). Our study provides experimental evidences that hyperglycernia could damage myocardial ultrastructure. Moreover, we provided first evidence that down-regulation of cardio protective peptide MKP-1, the MAPK pathway negative regulator, in myocardium of streptozotocin-induced diabetic rats, which may contribute to the deterioration of cardiac function and lead to diabetic cardiomyopathy.
-
Two PI3K Signals: One for Size and One for Strength
DOI: https://doi.org/10.1126/stke.2002.152.tw354
2002-10-01
Abstract:Cardiac hypertrophy is associated with many types of heart disease and can ultimately lead to cardiac decompensation and heart failure. One pathway important for the regulation of cell size is the phosphoinositide 3-kinase (PI3K) pathway acting through a signaling cascade that includes protein kinase B (PKB, also known as Akt), glycogen synthase kinase 3β (GSK-3β), and S6 kinase (p70 S6K ). Crackower et al. analyzed mice with cardiac and skeletal muscle-targeted deletion of the lipid phosphatase PTEN (mckCRE-PTEN Δ/Δ ) that is responsible for termination of PI3K signaling by dephosphorylation of phosphatidylinositol 3-phosphate (PIP 3 ), the product of PI3K activity. The mckCRE-PTEN Δ/Δ mice had enlarged hearts without any evidence of cardiomyopathy or cardiac decompensation and enhanced phosphorylation of PKB, GSK-3β, and p70 S6K . These mice also had decreased cardiac contractility. Increased cardiac contractility was evident in mice deficient for the G protein-coupled receptor (GPCR)-regulated isoform of the catalytic subunit of PI3K, p110γ. Double-mutant mice with both the cardiac PTEN deficiency and the p110γ deficiency showed enlarged hearts without the decreased contractility seen in the mckCRE-PTEN Δ/Δ mice. The effect of the PTEN deficiency on heart size was eliminated in mice expressing dominant-negative p110α, the isoform coupled to receptor tyrosine kinases. Thus, there appear to be two PI3K pathways: one that regulates size through PIP 3 produced by p110α and one that regulates contractility through PIP 3 produced by p110γ. Further investigation of the signaling pathway downstream of p110γ suggested the involvement of adenosine 3′,5′-monophosphate (cAMP) and regulation of the β 2 -adrenergic receptor in the enhanced contractility seen in the p110γ -/- mice. M. A. Crackower, G. Y. Oudit, I. Kozieradzki, R. Sarao, H. Sun, T. Sasaki, E. Hirsch, A. Suzuki, T. Shioi, J. Irie-Sasaki, R. Sah, H.-Y. M. Cheng, V. O. Rybin, A. J. Oliveira-dos-Santos, J. L. Benovic, C. R. Kahn, S. Izumo, S. F. Steinberg, M. P. Wymann, P. H. Backx, J. M. Penninger, Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell 110 , 737-749 (2002). [Online Journal]
-
Toward Ameliorating Insulin Resistance: Targeting a Novel PAK1 Signaling Pathway Required for Skeletal Muscle Mitochondrial Function
Rekha Balakrishnan,Pablo A. Garcia,Rajakrishnan Veluthakal,Janice M. Huss,Joseph M. Hoolachan,Debbie C. Thurmond
DOI: https://doi.org/10.3390/antiox12091658
IF: 7.675
2023-08-23
Antioxidants
Abstract:The p21-activated kinase 1 (PAK1) is required for insulin-stimulated glucose uptake in skeletal muscle cells. However, whether PAK1 regulates skeletal muscle mitochondrial function, which is a central determinant of insulin sensitivity, is unknown. Here, the effect of modulating PAK1 levels (knockdown via siRNA, overexpression via adenoviral transduction, and/or inhibition of activation via IPA3) on mitochondrial function was assessed in normal and/or insulin-resistant rat L6.GLUT4myc and human muscle (LHCN-M2) myotubes. Human type 2 diabetes (T2D) and non-diabetic (ND) skeletal muscle samples were also used for validation of the identified signaling elements. PAK1 depletion in myotubes decreased mitochondrial copy number, respiration, altered mitochondrial structure, downregulated PGC1α (a core regulator of mitochondrial biogenesis and oxidative metabolism) and PGC1α activators, p38 mitogen-activated protein kinase (p38MAPK) and activating transcription factor 2 (ATF2). PAK1 enrichment in insulin-resistant myotubes improved mitochondrial function and rescued PGC1α expression levels. Activated PAK1 was localized to the cytoplasm, and PAK1 enrichment concurrent with p38MAPK inhibition did not increase PGC1α levels. PAK1 inhibition and enrichment also modified nuclear phosphorylated-ATF2 levels. T2D human samples showed a deficit for PGC1α, and PAK1 depletion in LHCN-M2 cells led to reduced mitochondrial respiration. Overall, the results suggest that PAK1 regulates muscle mitochondrial function upstream of the p38MAPK/ATF2/PGC1α-axis pathway.
biochemistry & molecular biology,chemistry, medicinal,food science & technology
-
Cardiac PI3K p110α attenuation delays aging and extends lifespan
Mahmoud Abdellatif,Tobias Eisenberg,Alexander Martin Heberle,Kathrin Thedieck,Guido Kroemer,Simon Sedej
DOI: https://doi.org/10.15698/cst2022.08.270
2022-08-08
Cell Stress
Abstract:Phosphoinositide 3-kinase (PI3K) is a key component of the insulin signaling pathway that controls cellular me-tabolism and growth. Loss-of-function mutations in PI3K signaling and other downstream effectors of the insulin signaling pathway extend the lifespan of various model organisms. However, the pro-longevity effect appears to be sex-specific and young mice with reduced PI3K signaling have increased risk of cardiac disease. Hence, it remains elusive as to whether PI3K inhibition is a valid strategy to delay aging and extend healthspan in humans. We recently demonstrated that reduced PI3K activity in cardiomyocytes delays cardiac growth, causing subnormal contractility and cardiopulmonary functional capacity, as well as increased risk of mortality at young age. In stark contrast, in aged mice, experi-mental attenuation of PI3K signaling reduced the age-dependent decline in cardiac function and extended maximal lifespan, suggesting a biphasic effect of PI3K on cardiac health and survival. The cardiac anti-aging effects of reduced PI3K activity coincided with enhanced oxida-tive phosphorylation and required increased autophagic flux. In humans, explanted failing hearts showed in-creased PI3K signaling, as indicated by increased phos-phorylation of the serine/threonine-protein kinase AKT. Hence, late-life cardiac-specific targeting of PI3K might have a therapeutic potential in cardiac aging and related diseases.
-
Phosphoinositide 3-Kinase C2alpha controls cardiac contractility through regulation of beta2-adrenergic receptor recycling
S Cnudde,T Brand,J Fender,L Prever,A Murabito,M Russo,F Gulluni,K Lorenz,E Hirsch,A Ghigo
DOI: https://doi.org/10.1093/cvr/cvae088.017
IF: 13.081
2024-05-31
Cardiovascular Research
Abstract:Funding Acknowledgements Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Doctoral fellowship Introduction Phosphoinositide 3-kinase C2α (PI3KC2α) is a ubiquitously expressed class II PI3K isoform, which has been previously shown to be involved in the control of vesicular trafficking. However, its role in the myocardium has not been investigated. The primary aim of this study is to elucidate the mechanism by which mechanism PI3KC2α controls cardiac pathophysiology. Methods Cardiomyocyte-specific PI3KC2α knockout (PI3KC2α KO) animals were generated by crossing mice expressing a tamoxifen-inducible Cre recombinase under the control of the αMHC promoter with PI3KC2αflox/flox mice. Zebrafish embryos were injected with a PI3KC2α (PI3KC2α morphants) or a control morpholino (control morphants) at 1-cell stage. HEK293 with stable overexpression of GFP-tagged β2-AR were generated and transfected with either scramble or PI3KC2α siRNAs. Results Our findings indicate that PI3KC2α KO mice display a reduced cardiac contractility compared to wildtype animals. Similarly, PI3KC2α morphants zebrafish exhibit lower heart rate and fractional shortening compared to controls, both at baseline and after isoproterenol (ISO) stimulation. A similar unresponsiveness to ISO was found in vivo in PI3KC2α KO mice where chronic treatment with the β-adrenergic receptor (β-AR) agonist failed to induce the classical β-AR-mediated remodeling, characterized by an increase of the left ventricular mass and of cardiomyocyte area. These findings suggest that PI3KC2α plays a critical role in the regulation of β-AR signaling. In agreement, cAMP levels failed to increase in response to ISO treatment in PI3KC2α morphants. Furthermore, silencing of PI3KC2α in HEK293-GFP-β2-AR cells resulted in an increased GFP-β2-AR internalization compared to control cells, both at baseline and after ISO stimulation. Interestingly, preliminary findings indicate that overexpression of constitutively active Rab11Q70L induced a redistribution of GFP-β2-AR at the plasma membrane in PI3KC2α-silenced cells. Conclusion Overall, we identify a key role for PI3KC2α in the control of cardiac contractility through the regulation of β2-AR trafficking to the plasma membrane through a Rab11-dependent mechanism.
cardiac & cardiovascular systems
-
Abstract 3142: Pik3c3 Safeguards Smooth Muscle Identity by Promoting Lysosome-mediated Yap1 Degradation
Jian Shen,Xiangqin He,Kunzhe Dong,Guoqing Hu,Jian-Kang Chen,Zheng Dong,Huabo Su,David Fulton,Meixiang Xiang,Jiliang Zhou
DOI: https://doi.org/10.1161/atvb.44.suppl_1.3142
2024-01-01
Abstract:Background: Mature vascular smooth muscle cells (VSMCs) are quiescent and geared for maintaining vascular homeostasis by expressing a unique repertoire of contractile genes. However, key factors in controlling the contractile phenotype of VSMCs are poorly defined. Class III PI3K, PIK3C3 (Phosphatidylinositol 3-Kinase Catalytic Subunit Type 3) is a critical regulator of vesicular trafficking. Although PIK3C3 is known to play an essential role in cardiac homeostasis, its role in VSMCs remains elusive. Methods: To elucidate the role of Pik3c3 in regulating SMC fate and plasticity, we generated smooth muscle-specific Pik3c3 inducible knock out (KO) mice with SMC-lineage tracing. Proteomic mass spectrometry, next-generation RNA sequencing, SMC fate mapping coupled with single-cell RNA sequencing were applied to determine the phenotype and trajectories of SMCs after Pik3c3 ablation. Results: Specific ablation of Pik3c3 in SMCs results in severe gastrointestinal pseudo-obstruction and premature death. Analysis of aorta from the KO mice revealed dramatic vascular remodeling including dilatation, thickening of the vascular wall, spontaneous neointimal formation that was largely contributed by cells of SMC origin, and complete loss of contractility. Proteomics, bulk RNA-seq, and scRNA-seq studies of SMC-restricted Pik3c3 KO mouse aorta showed near complete loss of smooth muscle identity and the acquisition of an intermediate smooth muscle progenitor-like cell phenotype that underwent re-programming into multiple cell types including macrophages, T cells and osteoblasts. Mechanistically, we found that Pik3c3 deletion in VSMCs induces the accumulation of YAP1 (Yes associated protein 1) and its downstream target genes; this elevated YAP1 program appears to result from a blockade of autophagic lysosome-mediated degradation of YAP1, leading to phenotypic modulation of SMCs. Importantly, pharmacological inhibition of YAP by Verteporfin or genetic deletion of Yap1 rescues the vascular phenotype of Pik3c3 SM-specific KO mice. Conclusion: Our study reveals PIK3C3 as a master regulator safeguarding VSMC identity, and perturbation of the PIK3C3-YAP axis may be a novel mechanism underlying VSMC-driven vascular diseases in humans.
-
Type 1 Diabetes Impairs Vascular Relaxation Via Increases in Endothelial Glycolysis and Activation of the HIF1a-PFKFB3-Nox1 Pathway in Mice.
Reem Atawia,Thiago Bruder do Nascimento,Robert Batori,Simone Kennard,Galina Antonova,Coleton Jordan,Vinay Mehta,Masuko Ushio-Fukai,Tohru Fukai,Yuqing Huo,Vijay Patel,David Fulton,Eric Belin de Chantemele
DOI: https://doi.org/10.1152/physiol.2023.38.s1.5732305
IF: 11.8461
2023-01-01
Physiology
Abstract:Type 1 diabetes (T1D), which prevalence is currently on the rise, is a major risk factor for cardiovascular disease (CVD). Although T1D induces endothelial dysfunction, a precursor and contributor to CVD, its etiology remains ill-defined. Aberrant increases in endothelial cell (EC) glycolysis mainly via increased expression/ activity of its regulatory enzyme, 6-phosphofructo-2- kinase/fructose-2, 6-bisphosphatase 3 (PFKFB3) contribute to several vascular disorders. Nevertheless, whether alterations in EC glycolysis impairs endothelium dependent relaxation (EDR) is unknown. Using Akita mice, a genetic model of T1D, and a newly developed assay to measure EC glycolytic capacity in aortic explants via Seahorse analyzer, we tested the hypothesis that T1D impairs endothelial function via increasing EC glycolysis. Aortic explants from Akita mice exhibited a 1.7-fold increase in glycolysis to WT (P<0.05). EC-denudation abolished these increases which identify EC as the source of increased vascular glycolysis. These metabolic changes were accompanied by a 2-fold increase in EC PFKFB3 expression in aortas of Akita mice and inhibition of PFKFB3 using 3PO restored EDR in Akita mice. Interestingly, increases in EC glycolysis in situ via transduction of adenoviral vectors to overexpress either PFKFB3 (Ad-PFKFB3) or a constitutively active form of PFK2 to drive glycolysis independent of PFKFB3 (Ad-GlycoHi) reproduced the endothelial dysfunction associated with T1D. Also, EC transduced in vitro with Ad-PFKFB3 depicted increased expression of the ROS–producing enzyme, NADPH oxidase homolog, Nox1, and its co-activator, NoxA1(p<0.05). Similarly, aorta EC from Akita mice revealed increased Nox1 and NoxA1 expression. Inhibition of Nox1 fully restored EDR in Akita and Ad-PFKFB3-transduced WT aortas. Consistently, aortas from Nox1 KO mice were protected from Ad-PFKFB3-induced endothelial dysfunction. T1D markedly increased the aortic expression of the Advanced Glycation End products (AGE) precursor methylglyoxal (MG) (p<0.05), thus, we tested the contribution of AGE to T1D-induced EC glycolysis. Aortic rings exposed to MG showed increased EC PFKFB3 and Nox1 expression and impaired EDR. The latter was restored in rings incubated with 3PO or in rings from EC-specific PFKFB3 deficient mice (p<0.05). Also, T1D and exposure to MG upregulated hypoxia-inducible factor 1α(HIF1α) expression in EC. HIF1α inhibition blunted MG-mediated PFKFB3 upregulation in aorta EC (p<0.05). In Conclusion, this study identified for the first time a role for endothelial PFKFB3-mediated glycolysis in T1D-induced endothelial dysfunction. The underlying mechanism involves AGE and HIF1α as upstream regulators and NOX1 as a downstream target for PFKFB3. Thus, PFKFB3 and Nox1 inhibitors are potential therapeutic targets for diabetes-induced vascular complications. R01s (1R01HL147639-01A1 and 1R01HL155265-01) and 19EIA34760167 to E.J. Belin de Chantemèle. APS APHYS00010 and 2020AHA000POST000204982 to R.T.Atawia This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.
-
PI3 kinase delta governs regulatory T-cell biology and thus confers protection against atherosclerosis progression in mice
M Zierden,E M Berghausen,L Gnatzy-Feik,C Millarg,F S R Picard,M Kiljan,S Geissen,A Polykratis,L Zimmermann,M Pasparakis,S Baldus,H Winkels,M Vantler,S Rosenkranz
DOI: https://doi.org/10.1093/eurheartj/ehae666.3892
IF: 39.3
2024-10-30
European Heart Journal
Abstract:Introduction and Purpose Atherosclerosis is a chronic inflammatory disease of arteries, critically involving innate and adaptive immune cells like macrophages as well as T and B lymphocytes. Macrophages are major drivers of disease through the ingestion of lipoproteins, foam cell formation, and secretion of inflammatory mediators. Although macrophages outnumber other leukocytes in atherosclerotic plaques, T and B cells can shape the course of disease by promoting or mitigating inflammatory responses. The phosphoinositide 3-kinase delta (PI3Kd) exerts a key role in the regulation of immune responses including activation, proliferation, differentiation, and effector function of lymphocytes. Therefore, PI3Kd may represent a promising target for the modulation of inflammatory diseases. Consequently, we aimed to analyse the role of PI3Kd during atherogenesis. Methods and Results To investigate the role of haematopoietic PI3Kd in atherosclerosis, bone marrow from PI3Kd-/- or PI3Kd+/+ mice was transplanted into Ldlr-/- mice. After a 6-weeks-challenge by high fat diet, PI3Kd-/- recipient Ldlr-/- mice displayed profoundly impaired CD4+ and CD8+ T-cell numbers, CD4+ T-cell activation, CD4+ effector T-cell differentiation, and proatherogenic CD4+ T-helper (Th) 1 responses in para-aortic lymph nodes and spleen compared with PI3Kd+/+ transplanted controls. Surprisingly, the net effect of PI3Kd deficiency was a substantial increase of aortic inflammation and atherosclerosis in Ldlr-/- mice. Whereas plaque content and functions of macrophages including foam cell formation, efferocytosis, and cytokine secretion remained largely unaffected, haematopoietic PI3Kd ablation strongly reduced mature B cells and serum immunoglobulins in Ldlr-/- mice. Importantly, PI3Kd deficiency severely impaired numbers, proliferation, immunosuppressive functions, and stability of regulatory CD4+ T cells (Tregs). Consequently, adoptive transfer of PI3Kd+/+ Tregs fully restrained the atherosclerotic plaque burden in PI3Kd-/- transplanted Ldlr-/- mice without affecting B-cell numbers and serum immunoglobulins, whereas transferred PI3Kd-/- Tregs failed to relieve atherosclerosis progression. Conclusions Here, we demonstrate that PI3Kd plays a crucial role in Tregs, Th1 cells, and B cells during atherogenesis. Lack of PI3Kd signalling specifically in atheroprotective Treg responses outplays its impact on B-cell and proatherogenic Th1 responses, thus leading to aggravated atherosclerosis. Hence, PI3Kd is a key regulator of Treg biology and thereby protects against atherosclerosis, suggesting that fine-tuning PI3Kd signalling may represent a promising target for Treg-directed therapy.
cardiac & cardiovascular systems
-
Abstract 109: PI3Kγ Regulates Release of Myocyte-derived Factors Responsible for Myofibroblast Differentiation and Cardiac Fibrosis
Maradumane L Mohan,Lisa M Grove,Robert S Papay,Elizabeth E Martelli,Belinda B Willard,Mitchell A Olman,Sathyamangla V Naga Prasad
DOI: https://doi.org/10.1161/res.121.suppl_1.109
IF: 23.213
2017-07-21
Circulation Research
Abstract:Phosphoinositide 3 Kinase γ (PI3Kγ) is a lipid kinase that regulates downstream anti-apoptotic Akt signaling. Thus, pressure overload in PI3Kγ null (PI3Kγ -/- ) mice leads to significant cardiac fibrosis, a key underlying cause of fatal heart failure. Classical hallmark of tissue fibrosis is differentiation of fibroblasts to myofibroblasts characterized by smooth muscle α-actin (αSMA) overexpression. However, less is known about the role of PI3Kγ in cardiac myofibroblast differentiation. Assessment of αSMA expression in cardiac lysates from WT and PI3Kγ -/- showed significant baseline upregulation in PI3Kγ -/- showing that loss of PI3Kγ predisposes the hearts towards fibrosis. To directly confirm that PI3Kγ -/- cardiac fibroblasts (CF) exhibit a myofibroblast phenotype, CF were isolated from hearts of WT and PI3Kγ -/- and assessed by immunostaining for αSMA in stress fibers. Greater number of CF from PI3Kγ -/- exhibited αSMA in stress fibers than CF from WT. Correspondingly, immunoblotting showed significantly higher expression of αSMA in PI3Kγ -/- CF compared to WT showing enhanced myofibroblast differentiation by PI3Kγ -/- fibroblasts. Surprisingly, abundance of αSMA protein is significantly reduced in the hearts of mice with cardiomyocyte-specific expression of kinase-dead PI3Kγ (PI3Kγ inact ) in the PI3Kγ -/- (PI3Kγ inact /PI3Kγ -/- ) suggesting that myocytes derived factors responsible for myofibroblast differentiation are regulated by kinase-independent function of PI3Kγ. To directly evaluate the PI3Kγ-dependent cardiomyocyte derived factors responsible for myofibroblast differentiation; fibroblasts were treated with conditioned media derived from primary adult cardiomyocytes from WT, PI3Kγ -/- and PI3Kγ inact /PI3Kγ -/- mice. Conditioned media derived from PI3Kγ -/- showed pro-fibrotic effects, while that from PI3Kγ inact /PI3Kγ -/- showed fibrosis protective biological activity compared to WT. These findings reveal that kinase-independent function of PI3Kγ is a key regulator of the myocyte-initiated pathway that ultimately drives myofibroblast conversion. Proteomic analysis of conditioned media identified several pro-fibrotic factors that are regulated by PI3Kγ, the results of which will be discussed.
cardiac & cardiovascular systems,peripheral vascular disease,hematology
-
Pi 3-Kinase and Its Up- and Down-Stream Modulators As Potential Targets for the Treatment of Type II Diabetes.
Guoqiang Jiang,Bei B Zhang
DOI: https://doi.org/10.2741/jiang
2002-01-01
Frontiers in Bioscience
Abstract:Type 2 diabetes is caused by a combination of impaired insulin secretion and, to a greater extent, resistance of target tissues to insulin action. Phosphoinositide 3-kinase (PI3K) plays a key role in insulin signaling and has been shown to be blunted in tissues of type 2 diabetes subjects. There is emerging biochemical and, particularly, genetic evidence suggesting that insulin resistance can potentially be treated via modulation of PI3K by targeting PI3K itself or its up and down-stream modulators. These potential targets include Src homology 2 domain containing inositol 5-phosphatase 2 (SHIP2), phosphatase and tensin homolog deleted on chromosome ten (PTEN), kappaB kinase beta (IKKbeta), PKC isoforms, and the PI3K p85 subunit. There is evidence suggesting that their inhibition affects PI3K activity and improves insulin sensitivity in vivo. In the current review, we will discuss the role of these molecules in insulin-mediated activation of PI3K, the rational for targeting these molecules for diabetes treatment, and some critical issues in terms of drug development.
-
Increased insulin sensitivity and hypoglycaemia in mice lacking the p85α subunit of phosphoinositide 3–kinase
Yasuo Terauchi,Youki Tsuji,Shinobu Satoh,Hideaki Minoura,Koji Murakami,Akira Okuno,Kouichi Inukai,Tomoichiro Asano,Yasushi Kaburagi,Kohjiro Ueki,Hiromu Nakajima,Toshiaki Hanafusa,Yuji Matsuzawa,Hisahiko Sekihara,Yuxin Yin,J. Carl Barrett,Hideaki Oda,Takatoshi Ishikawa,Yasuo Akanuma,Issei Komuro,Misao Suzuki,Ken-ichi Yamamura,Tatsuhiko Kodama,Harumi Suzuki,Shigeo Koyasu,Shinichi Aizawa,Kazuyuki Tobe,Yasuhisa Fukui,Yoshio Yazaki,Takashi Kadowaki
DOI: https://doi.org/10.1038/6023
IF: 30.8
1999-01-01
Nature Genetics
Abstract:The hallmark of type 2 diabetes, the most common metabolic disorder, is a defect in insulin–stimulated glucose transport in peripheral tissues. Although a role for phosphoinositide–3–kinase (PI3K) activity in insulin–stimulated glucose transport and glucose transporter isoform 4 (Glut4) translocation has been suggested in vitro 1 , 2 , its role in vivo and the molecular link between activation of PI3K and translocation has not yet been elucidated. To determine the role of PI3K in glucose homeostasis, we generated mice with a targeted disruption of the gene encoding the p85α regulatory subunit of PI3K ( Pik3r1 ; refs 3 , 4 , 5 ). Pik3r1 −/− mice showed increased insulin sensitivity and hypoglycaemia due to increased glucose transport in skeletal muscle and adipocytes. Insulin–stimulated PI3K activity associated with insulin receptor substrates (IRSs) was mediated via full–length p85α in wild–type mice, but via the p50α alternative splicing isoform of the same gene 6 , 7 in Pik3r1 −/− mice. This isoform switch was associated with an increase in insulin–induced generation of phosphatidylinositol(3,4,5)triphosphate (PtdIns(3,4,5)P 3 ) in Pik3r1 −/− adipocytes and facilitation of Glut4 translocation from the low–density microsome (LDM) fraction to the plasma membrane (PM). This mechanism seems to be responsible for the phenotype of Pik3r1 −/− mice, namely increased glucose transport and hypoglycaemia. Our work provides the first direct evidence that PI3K and its regulatory subunit have a role in glucose homeostasis in vivo .
-
Increased insulin sensitivity and hypoglycaemia in mice lacking the p85 alpha subunit of phosphoinositide 3-kinase.
Y Terauchi,Y Tsuji,S Satoh,H Minoura,K Murakami,A Okuno,K Inukai,T Asano,Y Kaburagi,K Ueki,H Nakajima,T Hanafusa,Y Matsuzawa,H Sekihara,Y Yin,J C Barrett,H Oda,T Ishikawa,Y Akanuma,I Komuro,M Suzuki,K Yamamura,T Kodama,H Suzuki,K Yamamura,T Kodama,H Suzuki,S Koyasu,S Aizawa,K Tobe,Y Fukui,Y Yazaki,T Kadowaki
DOI: https://doi.org/10.1038/6023
IF: 30.8
1999-01-01
Nature Genetics
Abstract:The hallmark of type 2 diabetes, the most common metabolic disorder, is a defect in insulin-stimulated glucose transport in peripheral tissues. Although a role for phosphoinositide-3-kinase (PI3K) activity in insulin-stimulated glucose transport and glucose transporter isoform 4 (Glut4) translocation has been suggested in vitro(1,2), its role in vive and the molecular link between activation of PI3K and translocation has not yet been elucidated. To determine the role of PI3K in glucose homeostasis, we generated mice with a targeted disruption of the gene encoding the p85 alpha regulatory subunit of PI3K (Pik3r1; refs 3-5). Pik3r1(-/-) mice showed increased insulin sensitivity and hypoglycaemia due to increased glucose transport in skeletal muscle and adipocytes. Insulin-stimulated PI3K activity associated with insulin receptor substrates (IRSs) was mediated via full-length p85 alpha in wild-type mice, but via the p50 alpha alternative splicing isoform of the same gene(6,7) in Pik3r1(-/-) mice. This isoform switch was associated with an increase in insulin-induced generation of phosphatidylinositol(3, 4, 5)triphosphate (PtdIns(3, 4, 5)P-3) in Pik3r1(-/-) adipocytes and facilitation of Glut4 translocation from the law-density microsome (LDM) fraction to the plasma membrane (PM). This mechanism seems to be responsible for the phenotype of Pik3r1(-/-) mice, namely increased glucose transport and hypoglycaemia. Our work provides the first direct evidence that PI3K and its regulatory subunit have a role in glucose homeostasis in vive.
-
Inhibition of proline-rich-tyrosine kinase 2 restores cardioprotection by remote ischemic preconditioning in type 2 diabetes mellitus
Ralf Erkens,Dragos Duse,Amanda Brum,Alexandra Chadt,Stefanie Becher,Mauro Siragusa,Christine Quast,Johanna Müssig,Michael Roden,Miriam Cortese-Krott,Eckhard Lammert E,Ingrid Fleming,Christian Jung,Hadi Al-Hasani,Gerd Heusch,Malte Kelm
DOI: https://doi.org/10.1101/2023.04.25.538211
2023-05-01
Abstract:Abstract Background Endothelial function and cardioprotection through remote ischemic preconditioning (rIPC) are severely impaired in type 2 diabetes mellitus (T2DM). Proline-rich tyrosine kinase 2 (Pyk2), a downstream target of the insulin receptor, reduces endothelial nitric oxide synthase (eNOS) activity. Therapeutic options to rescue cardioprotection in T2DM and improve outcomes after acute myocardial infarction (AMI) are lacking. We hypothesized that vascular endothelium contributes to rIPC, and that inhibition of Pyk2 restores cardioprotection in T2DM through modulation of eNOS, thus limiting infarct size. Methods New Zealand Obese (NZO) mice were used as a polygenic model of T2DM. Effects of Pyk2-inhibition on endothelial function, remote ischemic preconditioning (rIPC), and infarct size (IS) after ischemia/reperfusion (I/R) were compared in NZO, eNOS KO, and C57Bl/6 (Bl6) mice. Plasma derived from mice and individuals with or without T2DM at baseline and after rIPC was transferred to isolated hearts and aortic rings to assess the effects of Pyk2-inhibition on remote tissue protection. Results Transfer experiments with plasma drawn from non-diabetic humans and mice exposed to rIPC demonstrate that endothelium-dependent signals for remote tissue protection are conveyed by plasma. Key features reflecting the glucometabolic spectrum in T2DM were detected in NZO mice, including hyperinsulinemia, insulin resistance, obesity, and impaired glucose tolerance. Similar to T2DM patients, these mice also revealed endothelial dysfunction with decreased flow-mediated dilation (FMD), reduced circulating nitrite levels, elevated arterial blood pressure, and larger infarct size after I/R. Pyk2 increased the phosphorylation of eNOS on its inhibitory site (Tyr656). Cardioprotective effects by rIPC were lost in NZO mice. Inhibition of Pyk2 restored endothelial function and rescued endothelium-dependent cardioprotection after rIPC displayed by lower IS and improved LV function post I/R. Conclusion Endothelial function contributing to remote tissue protection is severely impaired in diabetes mellitus. Proline-rich tyrosine kinase 2 is a novel target to rescue cardioprotection through endothelium-dependent remote ischemic preconditioning, advocating its role in limiting infarct size in diabetes mellitus. Clinical perspective What is new? Vascular endothelium contributes to remote tissue protection in ischemic preconditioning, which is severely impaired in diabetes Proline-rich tyrosine kinase 2 reduces eNOS-activity, causes endothelial dysfunction, and impairs cardioprotection through ischemic preconditioning Inhibition of proline-rich tyrosine kinase 2 restores eNOS activity, endothelial function, and cardioprotective effects of remote ischemic preconditioning limiting infarct size in an experimental model of diabetes. What are the clinical implications? Proper endothelial function is cirtical to maintain cardiovascular health. Endothelial dysfunction contributes to impaired remote tissue protection in diabetes. These data demonstrate for the first time that endothelium-dependent cardioprotection in myocardial ischemia/reperfusion through remote ischemic preconditioning can be restored in diabetes. Proline-rich tyrosine kinase 2 is a novel target to restore endothelium-dependent remote cardioprotection to improve the outcome of diabetic patients with acute myocardial infarction.
-
Inhibition of PI-3 Kinase/akt/mtor, but Not Calcineurin Signaling, Reverses Insulin-Like Growth Factor I-induced Protection Against Glucose Toxicity in Cardiomyocyte Contractile Function
SY Li,CX Fang,NS Aberle,BH Ren,AF Ceylan-Isik,J Ren
DOI: https://doi.org/10.1677/joe.1.06168
2005-01-01
Abstract:Insulin-like growth factor-I (IGF-1) ameliorates cardiac dysfunction in diabetes although the mechanism of action remains poorly understood. This study examined the role of PI-3 kinase/Akt/mammalian target of rapamycin (mTOR) and calcineurin pathways in cardiac effects of IGF-1 against glucose toxicity. Adult rat ventricular myocytes were cultured for 8 h with either normal (NG, 5.5 mM) or high (HG, 25.5 mM) glucose, in the presence or absence of IGF-1 (10-500 nM), the PI-3 kinase/Akt inhibitor LY294002 (10 microM), the mTOR inhibitor rapamycin (20 microM) or the calcineurin inhibitors cyclosporin A (5 microM) or FK506 (10 mg/l). Mechanical properties were evaluated using an IonOptix MyoCam system. HG depressed peak shortening (PS), reduced maximal velocity of shortening/relengthening (+/- dl/dt) and prolongs time-to-90% relengthening (TR90), which were abolished by IGF-1 (100 and 500 nM). Interestingly, the IGF-1-elicited protective effect against HG was nullified by either LY294002 or rapamycin, but not by cyclosporine A or FK506. None of the inhibitors affected cell mechanics. Western blot analysis indicated that HG and IGF-1 stimulated phosphorylation of Akt and mTOR. HG also activated p70s6k and suppressed GSK-3beta phosphorylation. However, the HG-induced alterations in phosphorylation of Akt, mTOR, p70s6k and GSK-3beta were significantly reversed by IGF-1. Protein expression of Akt, mTOR, p70s6k, GSK-3beta, SERCA2a and phospholamban was unaffected by HG, IGF-1 or rapamycin. Rapamycin significantly enhanced Akt phosphorylation whereas it inhibited mTOR phosphorylation. Collectively, our data suggest that IGF-1 may provide cardiac protection against glucose in part through a PI-3 kinase/Akt/mTOR/ p70s6k-dependent and calcineurin-independent pathway.
-
Inhibition of the PI 3-kinase pathway disrupts the unfolded protein response and reduces sensitivity to ER stress-dependent apoptosis
Jonathon N Winnay,Marie H Solheim,Masaji Sakaguchi,Pål R Njølstad,C Ronald Kahn
DOI: https://doi.org/10.1096/fj.202000892R
Abstract:Class Ia phosphoinositide 3-kinases (PI3K) are critical mediators of insulin and growth factor action. We have demonstrated that the p85α regulatory subunit of PI3K modulates the unfolded protein response (UPR) by interacting with and regulating the nuclear translocation of XBP-1s, a transcription factor essential for the UPR. We now show that PI3K activity is required for full activation of the UPR. Pharmacological inhibition of PI3K in cells blunts the ER stress-dependent phosphorylation of IRE1α and PERK, decreases induction of ATF4, CHOP, and XBP-1 and upregulates UPR target genes. Cells expressing a human p85α mutant (R649W) previously shown to inhibit PI3K, exhibit decreased activation of IRE1α and PERK and reduced induction of CHOP and ATF4. Pharmacological inhibition of PI3K, overexpression of a mutant of p85α that lacks the ability to interact with the p110α catalytic subunit (∆p85α) or expression of mutant p85α (R649W) in vivo, decreased UPR-dependent induction of ER stress response genes. Acute tunicamycin treatment of R649W+/- mice revealed reduced induction of UPR target genes in adipose tissue, whereas chronic tunicamycin exposure caused sustained increases in UPR target genes in adipose tissue. Finally, R649W+/- cells exhibited a dramatic resistance to ER stress-dependent apoptosis. These data suggest that PI3K pathway dysfunction causes ER stress that may drive the pathogenesis of several diseases including Type 2 diabetes and various cancers.
-
PI3K Phosphorylation Is Linked to Improved Electrical Excitability in an In Vitro Engineered Heart Tissue Disease Model System
Kujaany Kana,Hannah Song,Carol Laschinger,Peter W Zandstra,Milica Radisic
DOI: https://doi.org/10.1089/ten.TEA.2014.0412
Abstract:Myocardial infarction, a prevalent cardiovascular disease, is associated with cardiomyocyte cell death, and eventually heart failure. Cardiac tissue engineering has provided hopes for alternative treatment options, and high-fidelity tissue models for drug discovery. The signal transduction mechanisms relayed in response to mechanoelectrical (physical) stimulation or biochemical stimulation (hormones, cytokines, or drugs) in engineered heart tissues (EHTs) are poorly understood. In this study, an EHT model was used to elucidate the signaling mechanisms involved when insulin was applied in the presence of electrical stimulation, a stimulus that mimics functional heart tissue environment in vitro. EHTs were insulin treated, electrically stimulated, or applied in combination (insulin and electrical stimulation). Electrical excitability parameters (excitation threshold and maximum capture rate) were measured. Protein kinase B (AKT) and phosphatidylinositol-3-kinase (PI3K) phosphorylation revealed that insulin and electrical stimulation relayed electrical excitability through two separate signaling cascades, while there was a negative crosstalk between sustained activation of AKT and PI3K.
-
Mice Carrying a Dominant-Negative Human PI3K Mutation Are Protected From Obesity and Hepatic Steatosis but Not Diabetes
Marie H Solheim,Jonathon N Winnay,Thiago M Batista,Anders Molven,Pål R Njølstad,C Ronald Kahn
DOI: https://doi.org/10.2337/db17-1509
IF: 7.7
Diabetes
Abstract:Phosphatidylinositol 3-kinase (PI3K) plays a central role in insulin signaling, glucose metabolism, cell growth, cell development, and apoptosis. A heterozygous missense mutation (R649W) in the p85α regulatory subunit gene of PI3K (PIK3R1) has been identified in patients with SHORT (Short stature, Hyperextensibility/Hernia, Ocular depression, Rieger anomaly, and Teething delay) syndrome, a disorder characterized by postnatal growth retardation, insulin resistance, and partial lipodystrophy. Knock-in mice with the same heterozygous mutation mirror the human phenotype. In this study, we show that Pik3r1 R649W knock-in mice fed a high-fat diet (HFD) have reduced weight gain and adipose accumulation. This is accompanied by reduced expression of several genes involved in lipid metabolism. Interestingly, despite the lower level of adiposity, the HFD knock-in mice are more hyperglycemic and more insulin-resistant than HFD-fed control mice. Likewise, when crossed with genetically obese ob/ob mice, the ob/ob mice carrying the heterozygous R649W mutation were protected from obesity and hepatic steatosis but developed a severe diabetic state. Together, our data demonstrate a central role of PI3K in development of obesity and fatty liver disease, separating these effects from the role of PI3K in insulin resistance and the resultant hyperglycemia.
-
piR112710 attenuates diabetic cardiomyopathy through inhibiting Txnip/NLRP3-mediated pyroptosis in db/db mice
Ande Jiao,Huaxing Liu,Huihui Wang,Jiaqi Yu,Lu Gong,Honglian Zhang,Lu Fu
DOI: https://doi.org/10.1016/j.cellsig.2024.111333
Abstract:PIWI-interacting RNAs (piRNAs) are involved in the regulation of hypertrophic cardiomyopathy, heart failure and myocardial methylation. However, their functions and the underlying molecular mechanisms in diabetic cardiomyopathy (DCM) have yet to be fully elucidated. In the present study, a pyroptosis-associated piRNA (piR112710) was identified that ameliorates cardiac remodeling through targeting the activation of inflammasomes and mitochondrial dysfunction that are mediated via the thioredoxin-interacting protein (Txnip)/NLRP3 signaling axis. Subsequently, the cardioprotective effects of piR112710 on both the myocardium from db/db mice and cardiomyocytes from neonatal mice that were incubated with a high concentration of glucose combined with palmitate were examined. piR112710 was found to significantly improve cardiac dysfunction in db/db mice, characterized by improved echocardiography, lower levels of fibrosis, attenuated expression levels of inflammatory factors and pyroptosis-associated proteins (namely, Txnip, ASC, NLRP3, caspase-1 and GSDMD-N), and enhanced myocardial mitochondrial respiratory functions. In cultured neonatal mice cardiomyocytes, piR112710 deficiency and high glucose along with palmitate treatment led to significantly upregulated expression levels of pyroptosis associated proteins and collagens, oxidative stress, mitochondrial dysfunction and increased levels of inflammatory factors. Supplementation with piR112710, however, led to a reversal of the aforementioned changes induced by high glucose and palmitate. Mechanistically, the cardioprotective effect of piR112710 appears to be dependent upon effective elimination of reactive oxygen species and inactivation of the Txnip/NLRP3 signaling axis. Taken together, the findings of the present study have revealed that the piRNA-mediated inhibitory mechanism involving the Txnip/NLRP3 axis may participate in the regulation of pyroptosis, which protects against DCM both in vivo and in vitro. piR112710 may therefore be a potential therapeutic target for the reduction of myocardial injury caused by cardiomyocyte pyroptosis in DCM.
-
Hyperglycemia-Driven Inhibition of AMP-Activated Protein Kinase &agr;2 Induces Diabetic Cardiomyopathy by Promoting Mitochondria-Associated Endoplasmic Reticulum Membranes In Vivo
M. Zou,Yin Wu,Qiulun Lu,Zhonglin Xie,Kai Huang,Pei Wang,Sheng-nan Wu,Y. Qiu,Ye Ding,Xiaoxiang Mao
DOI: https://doi.org/10.1161/CIRCULATIONAHA.118.033552
IF: 37.8
2019-04-16
Circulation
Abstract:Background: Fundc1 (FUN14 domain containing 1), an outer mitochondrial membrane protein, is important for mitophagy and mitochondria-associated endoplasmic reticulum membranes (MAMs). The roles of Fundc1 and MAMs in diabetic hearts remain unknown. The aims of this study, therefore, were to determine whether the diabetes mellitus–induced Fundc1 expression could increase MAM formation, and whether disruption of MAM formation improves diabetic cardiac function. Methods: Levels of FUNDC1 were examined in the hearts from diabetic patients and nondiabetic donors. Levels of Fundc1-induced MAMs and mitochondrial and heart function were examined in mouse neonatal cardiomyocytes exposed to high glucose (HG, 30 mmol/L D-glucose for 48 hours), and in streptozotocin-treated cardiac-specific Fundc1 knockout mice and cardiac-specific Fundc1 knockout diabetic Akita mice, as well. Results: FUNDC1 levels were significantly elevated in cardiac tissues from diabetic patients in comparison with those from nondiabetic donors. In cultured mouse neonatal cardiomyocytes, HG conditions increased levels of Fundc1, the inositol 1,4,5-trisphosphate type 2 receptor (Ip3r2), and MAMs. Genetic downregulation of either Fundc1 or Ip3r2 inhibited MAM formation, reduced endoplasmic reticulum-mitochondrial Ca2+ flux, and improved mitochondrial function in HG-treated cardiomyocytes. Consistently, adenoviral overexpression of Fundc1 promoted MAM formation, mitochondrial Ca2+ increase, and mitochondrial dysfunction in cardiomyocytes exposed to normal glucose (5.5 mmol/L D-glucose). In comparison with nondiabetic controls, levels of Fundc1, Ip3r2, and MAMs were significantly increased in hearts from streptozotocin-treated mice and Akita mice. Furthermore, in comparison with control hearts, diabetes mellitus markedly increased coimmunoprecipitation of Fundc1 and Ip3r2. The binding of Fundc1 to Ip3r2 inhibits Ip3r2 ubiquitination and proteasome-mediated degradation. Cardiomyocyte-specific Fundc1 deletion ablated diabetes mellitus–induced MAM formation, prevented mitochondrial Ca2+ increase, mitochondrial fragmentation, and apoptosis with improved mitochondrial functional capacity and cardiac function. In mouse neonatal cardiomyocytes, HG suppressed AMP-activated protein kinase activity. Furthermore, in cardiomyocytes of Prkaa2 knockout mice, expression of Fundc1, MAM formation, and mitochondrial Ca2+ levels were significantly increased. Finally, adenoviral overexpression of a constitutively active mutant AMP-activated protein kinase ablated HG-induced MAM formation and mitochondrial dysfunction. Conclusions: We conclude that diabetes mellitus suppresses AMP-activated protein kinase, initiating Fundc1-mediated MAM formation, mitochondrial dysfunction, and cardiomyopathy, suggesting that AMP-activated protein kinase–induced Fundc1 suppression is a valid target to treat diabetic cardiomyopathy.
Medicine